• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Make that 2 new sick­le cell dis­ease block­buster hope­fuls OK’d by the FDA in just a few days

6 years ago
R&D
FDA+

Shares of Adamis crater on CRL; Boris John­son promis­es to dou­ble de­men­tia re­search fund­ing

6 years ago
News Briefing

CymaBay scraps key NASH, PSC pro­grams af­ter lead drug trig­gers safe­ty alarms — share price im­plodes

6 years ago
R&D

Ex-Pur­due CEO stands to earn a huge wind­fall in No­var­tis' buy­out of the Med­i­cines Co

6 years ago
People
Deals

‘Break­through’ blad­der can­cer drug spin­out gets $570M to back launch of a new gene ther­a­py in the US

6 years ago
Startups
Deals

The big drug hunters: No­var­tis’ $28B-plus deal spree makes Vas Narasimhan one of the top deal­mak­ers of our time

6 years ago

Roche, PTC will now get an FDA de­ci­sion on their SMA drug in 6 months — fac­ing off with Bio­gen, No­var­tis

6 years ago
R&D
FDA+

Aque­s­tive nabs FDA OK for oral film ver­sion of gener­ic ALS drug

6 years ago
Pharma
FDA+

Roche shows Tecen­triq/Avastin com­bo helps liv­er can­cer pa­tients live longer

6 years ago
R&D
China

Har­vard con­sor­tium blue­prints $50M cell and gene ther­a­py cen­ter — but can they ac­tu­al­ly fos­ter low­er drug prices?

6 years ago
R&D

Ac­quis­i­tive No­var­tis bags PC­SK9 play­er Med­Co for $9.7B, set­ting up a flank at­tack on Sanofi, Re­gen­eron and Am­gen

6 years ago
Deals
R&D

With lat­est 18-month da­ta cut, Take­da push­es to­ward 2021 launch of dengue vac­cine — can they side­step Sanofi's ...

6 years ago
R&D

Take­da an­nounces pos­i­tive new ALK+ lung can­cer da­ta as list of crizo­tinib suc­ces­sors widens

6 years ago
R&D

Cel­gene R&D vet jumps to biotech: 'It’s about short­en­ing the cy­cle'; No­var­tis ex­o­dus con­tin­ues as William Chou ...

6 years ago
Peer Review

Japan­ese biotech pitch­ing iP­SC-de­rived med for the heart gains $26M; An­dreessen Horowitz leads $4.1M seed fund­ing for ...

6 years ago
News Briefing

Team­ing up with NIH, Vi­iV buys in­to the next big thing in HIV: an­ti­bod­ies

6 years ago
Deals

FDA re­leas­es 81 prod­uct-spe­cif­ic guid­ances

6 years ago
Pharma
FDA+

Alexan­dria is think­ing big as it lays out plans for 1.6M square foot Bay Area biotech cam­pus

6 years ago
R&D

Put on hold mu­sic: Roche de­lays Spark buy­out for the 9th — and quite pos­si­bly not the last — time

6 years ago
R&D

Sanofi's strat­e­gy head to re­tire by month end, as com­pa­ny gears up for De­cem­ber strate­gic up­date

6 years ago
People
Pharma

Com­pound nes­tled in par­a­sitic worm of­fers promise as an­tibi­ot­ic against ob­sti­nate su­per­bugs

6 years ago
Discovery

As­traZeneca scores again: Calquence ap­proved for CLL as BTK race heats up

6 years ago
R&D

New epilep­sy com­pa­ny on the block wins FDA ap­proval for made-in-Ko­rea drug to treat fo­cal seizures

6 years ago
R&D
FDA+

Bio­gen's Al San­drock says the FDA needs to ap­prove their con­tro­ver­sial Alzheimer's drug — now

6 years ago
Bioregnum
R&D
First page Previous page 879880881882883884885 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times